ANNX insider trading
NasdaqGS HealthcareAnnexon, Inc.: insider trade history from SEC Form 4 filings.
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Company website: www.annexonbio.com
ANNX insider activity at a glance
FilingIQ tracks 170 insider transactions for ANNX in filings since Jul 28, 2020. The most recent transaction is dated Sep 24, 2026.
Across the full history, 37 open-market purchases
and 70 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ANNX insider trades is 57.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ANNX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ANNX?
- FilingIQ tracks 170 Form 4 insider transactions for ANNX (Annexon, Inc.), covering filings from Jul 28, 2020 onwards. 1 of those are dated within the last 90 days.
- Are ANNX insiders net buyers or net sellers?
- Across the full Form 4 history for ANNX, 37 transactions (22%) were open-market purchases and 70 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ANNX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ANNX in?
- Annexon, Inc. (ANNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $730.37M.
Methodology & sources
Every ANNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.